Akari Therapeutics, Plc
AKTX
$3.06
-$2.09-40.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.22% | -237.73% | 48.85% | 1.78% | -30.29% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -53.91% | 613.65% | -195.65% | 850.00% | 76.27% |
| Change in Net Operating Assets | 103.48% | -38.22% | -173.37% | -63.25% | 14.64% |
| Cash from Operations | -43.38% | 34.86% | -51.44% | -1.22% | -42.55% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 39.60% | 5.61% | 58.37% | 47.17% | -189.58% |
| Issuance of Common Stock | -- | -100.00% | 23.35% | -15.35% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Financing | 203.64% | -43.89% | 58.51% | -0.97% | 586.23% |
| Foreign Exchange rate Adjustments | 100.00% | -175.00% | -- | -- | -50.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,297.80% | -275.97% | 858.82% | -104.12% | 121.39% |